As of close of business last night, Macrogenics Inc’s stock clocked out at $17.54, down -5.24% from its previous closing price of $18.51. On the day, 875221 shares were traded.
Ratios:
To gain a deeper understanding of MGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
On March 04, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $12 to $24.
H.C. Wainwright Downgraded its Buy to Neutral on February 14, 2024, whereas the target price for the stock was revised from $12 to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 04 ’24 when Peters Jeffrey Stuart sold 51,395 shares for $15.55 per share. The transaction valued at 799,148 led to the insider holds 0 shares of the business.
Peters Jeffrey Stuart sold 19,625 shares of MGNX for $421,938 on Mar 06 ’24. The Senior VP and General Counsel now owns 8,895 shares after completing the transaction at $21.50 per share. On Mar 04 ’24, another insider, Risser Eric Blasius, who serves as the Chief Operating Officer of the company, sold 41,159 shares for $19.76 each. As a result, the insider received 813,501 and left with 38,900 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 18.68 while its Price-to-Book (P/B) ratio in mrq is 7.13.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $21.88, while it has fallen to a 52-week low of $4.29.
Shares Statistics:
A total of 62.07M shares are outstanding, with a floating share count of 58.71M. Insiders hold about 6.15% of the company’s shares, while institutions hold 95.25% stake in the company.
Earnings Estimates
As of right now, REGENXBIO Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $9.16, with high estimates of $17.54 and low estimates of $40.25.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Communication Services.
